Myasthenia gravis onset during rheumatic disease: a new paradoxical effect of anti-TNF alpha therapy?

Int J Rheum Dis. 2015 Mar;18(3):375-6. doi: 10.1111/1756-185X.12340. Epub 2014 Apr 7.

Authors

Vincenzo Bruzzese¹, Cinzia Marrese, Palma Scolieri, Cesare Hassan, Roberto Lorenzetti, Angelo Zullo

Affiliation

¹ Department of Internal Medicine, Rheumatology and Gastroenterology, 'Nuovo Regina Margherita' Hospital, Rome, Italy.

PMID: 24702703
DOI: 10.1111/1756-185X.12340

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Anti-Inflammatory Agents / adverse effects*
Arthritis, Psoriatic / diagnosis
Arthritis, Psoriatic / drug therapy*
Arthritis, Psoriatic / immunology
Biological Products / adverse effects*
Drug Substitution
Etanercept / adverse effects*
Humans
Immunocompromised Host
Male
Middle Aged
Myasthenia Gravis / chemically induced*
Myasthenia Gravis / diagnosis
Myasthenia Gravis / immunology
Myasthenia Gravis / therapy
Remission Induction
Risk Factors
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / immunology

Substances

Anti-Inflammatory Agents
Biological Products
Tumor Necrosis Factor-alpha
Etanercept